Beyond Thinking
Welcome to Beyond Blue’s Thought Leadership Hub, where we highlight complex concepts with clarity and showcase our commitment to delivering excellence with ease. Explore our insights, discover innovative perspectives and join us on a journey to navigate the intricate with confidence.
How can insight generation be more agile
Agile Online Communities We know brand teams are under immense time pressure ahead of launch and can feel like workstreams are waiting in suspense for insight programs to deliver. Can insight generation be more agile, and make better use of the research timeline? We...
Neoadjuvant Chemo-IO – a new standard for resectable NSCLC?
12 months ago, at ESMO 2021, the oncology community was asked, “Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?”. At that time, 71% felt the available efficacy data was not sufficient to implement...
Women in Science: Q&A with our team
Women in Science: Q&A with our team Women in Science Day takes place on Friday 11th February. It marks a global celebration of the women who work and contribute to the many scientific discoveries we see every day. At Blueprint, we support the involvement and...
Expert insights into future opportunities in immuno-oncology
It is widely accepted that the use of immunotherapy agents has been one of the major advances in oncology over recent years. But what further changes can we expect as the area develops in the next few years, and what does that mean for pharma? To look further into...
Pre-launch research is our speciality
The Beyond Blue Way A true strategic partner providing tangible deliverables that actually impact brand success Bringing blockbuster drugs that address significant medical needs to market is still considered the hallmark of productive, innovative R&D. In 2018, 56%...
Oncology Trends, Views and Perspectives from Beyond Blue
What are the leading oncology issues and drug development trends, outside of reimbursement/drug access? What is the impact of COVID–19 across oncology? How can we use market research methods to maximise stakeholder insights on future oncology drug development,...